Renaissance Technologies
GANX icon

Renaissance Technologies’s Gain Therapeutics GANX Stock Holding History

Renaissance Technologies’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,400
Closed -$56K – 3407
2025
Q4 		$56K Sell
17,400
-108,700
-86% -$290K ﹤0.01% 3081
2025
Q3 		$223K Buy
126,100
+32,100
+34% +$54.1K ﹤0.01% 3107
2025
Q2 		$169K Buy
+94,000
New +$174K ﹤0.01% 3201
2024
Q4 		– Sell
-53,264
Closed -$94.8K – 3692
2024
Q3 		$94.8K Sell
53,264
-65,436
-55% -$82.2K ﹤0.01% 3267
2024
Q2 		$152K Buy
118,700
+72,000
+154% +$187K ﹤0.01% 3103
2024
Q1 		$176K Buy
46,700
+3,900
+9% +$16.2K ﹤0.01% 3254
2023
Q4 		$140K Sell
42,800
-4,100
-9% -$11.4K ﹤0.01% 3227
2023
Q3 		$154K Sell
46,900
-700
-1% -$2.65K ﹤0.01% 3152
2023
Q2 		$213K Buy
47,600
+8,900
+23% +$43.4K ﹤0.01% 3277
2023
Q1 		$187K Buy
38,700
+5,500
+17% +$22.5K ﹤0.01% 3300
2022
Q4 		$104K Sell
33,200
-200
-0.6% -$625 ﹤0.01% 3605
2022
Q3 		$109K Buy
33,400
+300
+0.9% +$1.13K ﹤0.01% 3565
2022
Q2 		$119K Buy
+33,100
New +$114K ﹤0.01% 3801

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Renaissance Technologies's GANX Position: Q1 2026 in Review

Renaissance Technologies sold out of Gain Therapeutics (GANX) in Q1 2026, closing a stake of 17,400 shares — an estimated $56K sold.

Renaissance Technologies first reported a position in GANX in Q2 2022 and held it in 13 quarters. The position peaked at $223K in Q3 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • Renaissance Technologies reported no remaining Gain Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Renaissance Technologies sold 17,400 Gain Therapeutics shares in Q1 2026, an estimated $56K.
  • Renaissance Technologies first reported a position in Gain Therapeutics in Q2 2022 and held it in 13 quarters.
  • Renaissance Technologies's Gain Therapeutics position peaked at $223K in Q3 2025.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.